Abstract

Oncogenic Cooperation Between IL7R-JAK-STAT Pathway Mutations.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.
Maria Kleppe ... Jan Cools
Blood | VOL. 114
Maria Kleppe, et. al.Maria Kleppe ... Jan Cools
20 Nov 2009
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia
Maria Kleppe ... Idoya Lahortiga
Nature genetics | VOL. 42
Maria Kleppe, et. al.Maria Kleppe ... Idoya Lahortiga
16 May 2010
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling
Romain Duval ... Fernando Rodrigues-Lima
The Journal of biological chemistry | VOL. 294
Romain Duval, et. al.Romain Duval ... Fernando Rodrigues-Lima
01 Aug 2019
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Yunlei Li ... Eric M Vroegindeweij
PLoS Medicin | VOL. 13
Yunlei Li, et. al.Yunlei Li ... Eric M Vroegindeweij
20 Dec 2016
View more papers

More From: HemaSphere

Paper Title
Journal
Date
Author
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.
Andrew D Zelenetz ... Pier L Zinzani
HemaSphere | VOL. 8
Andrew D Zelenetz, et. al.Andrew D Zelenetz ... Pier L Zinzani
01 Aug 2024
Bone marrow niches for hematopoietic stem cells.
Ana Luísa Pereira ... César Nombela-Arrieta
HemaSphere | VOL. 8
Ana Luísa Pereira, et. al.Ana Luísa Pereira ... César Nombela-Arrieta
01 Aug 2024
Disease-burden-adapted immunotherapy protocol for primary refractory or high-risk relapsed pediatric acute lymphoblastic leukemia.
Sanaa Khan ... Prashant Hiwarkar
HemaSphere | VOL. 8
Sanaa Khan, et. al.Sanaa Khan ... Prashant Hiwarkar
01 Aug 2024
Improving CORM technology for the treatment of delayed hemolytic transfusion reaction.
Michela Asperti ... Francesca Vinchi
HemaSphere | VOL. 8
Michela Asperti, et. al.Michela Asperti ... Francesca Vinchi
01 Aug 2024
View more papers